Healthcare Industry News: Integrated BioPharma
News Release - May 7, 2007
OMRIX Biopharmaceuticals Submits Regulatory Filing for Hepatitis B Immunoglobulin (HBIG) in SwedenNEW YORK--(HSMN NewsFeed)--OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI ), a fully-Integrated BioPharmaceutical company that develops and markets protein-based biosurgery and passive immunotherapy products, announced today that the Company has submitted a regulatory filing to expand the commercialization of its Hepatitis B Immunoglobulin product, or HBIG, in Sweden.
"Our regulatory submission for HBIG in Sweden is part of our stated objective and strategy to launch our marketed immunotherapy products in new territories," stated Robert Taub, President and Chief Executive Officer of OMRIX Biopharmaceuticals, Inc. "Our HBIG product has done very well in Israel and we expect that once commercialized it will have the same success in Sweden. We anticipate that introducing HBIG in Sweden will allow us to submit additional filings throughout Europe."
The Company anticipates obtaining approval for HBIG in Sweden by the second quarter of 2008 (2Q08).
About Hepatitis B Immunoglobulin (HBIG)
HBIG is a product that contains antibodies specific to the Hepatitis B Virus, or HBV, which can cause lifelong infection, scarring of the liver, liver cancer, liver failure and death. Patients with chronic HBV often require a transplant. However, because HBV can reside in tissue other than the liver, there is a high risk of reinfection. This results in the transplanted liver becoming infected with HBV, which destroys the transplanted liver. To prevent reinfection, patients require lifelong treatment for HBV. OMRIX' HBIG is one of the treatments used to prevent reinfection of the transplanted liver.
About OMRIX Biopharmaceuticals, Inc.
OMRIX Biopharmaceuticals is a fully-Integrated BioPharmaceutical company developing and marketing protein-based biosurgery and passive immunotherapy products. OMRIX' biosurgery product line includes products and product candidates that are used for the control of bleeding, or hemostasis, and other surgical applications. OMRIX' novel Fibrin Patch, a biological-device convergence product candidate, addresses an unmet medical need. The Company's passive immunotherapy product line includes antibody-rich products and product candidates for the treatment of immune deficiencies, infectious diseases and potential bio-defense applications. For more information, please visit: www.omrix.com.
Safe Harbor Statement
This press release contains forward-looking statements. Forward-looking statements provide the company's current expectations or forecasts of future events. Forward-looking statements include statements about the Company's expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Forward-looking statements are subject to known and unknown risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially from those expected or implied by the forward-looking statements. The company's actual results could differ materially from those anticipated in forward-looking statements for many reasons, including the factors described in the company's filings with the SEC, including sections entitled "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's Form 10-K as filed with the Securities and Exchange Commission on March 13, 2007 and the company's most recent quarterly reports on Form 10-Q and its current reports on Form 8-K. Unless required by law, the company undertakes no obligation to publicly update or revise any forward-looking statement to reflect circumstances or events after the date of this press release.
Source: OMRIX Biopharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.